- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
GlobalData forecasts huge increase in psoriasis therapeutics market
13 April 2016 • Author: Mandy Parrett, Editorial Assistant
The psoriasis therapeutics market is set to more than double from $6.6 billion in 2014 to over $13.3 billion by 2024, according to research and consulting firm, GlobalData.
This significant increase represents an annual growth rate of 7.3% – an encouraging statistic for the 2-3% of sufferers throughout the world who are looking for relief from the chronic genetic skin disorder.
Psoriasis therapeutics market driven by many factors
GlobalData’s report states that this impressive growth will be driven by the launch of new psoriasis products, as well as the expansion of existing therapies – such as dimethyl fumarate from Germany into the US and major European markets – and the rapid uptake of biosimilars for currently marketed biologics. The patents for high-grossing branded drugs, such as TNF inhibitors, Humira, Enbrel and Remicade, in the US and 5EU in France, Germany, Italy, Spain and the UK are due to expire over the forecast period and will inevitably spread growth throughout the different levels of products in the coming years.
Unique drugs will enhance psoriasis therapeutics market
Nikhilesh Sanyal, Ph.D., GlobalData’s Analyst covering Immunology, explains: “Although the psoriasis market will be crowded, novel products such as Eli Lilly’s anti-interleukin(IL)-17 drug, ixekizumab, and Johnson & Johnson’s (J&J’s) IL-23 inhibitor, guselkumab, are expected to achieve sales in excess of $1 billion each by the end of the forecast period, primarily due to their high clinical efficacy and safety profiles.”
“Other pipeline therapies with exceptional efficacy and safety credentials include Merck’s tildrakizumab and AstraZeneca/Valeant’s brodalumab, which will go a long way towards addressing the current need for therapies that can provide long-lasting results without side effects or an increased risk of comorbidities.”
More information about the report can be found here: http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/pharmapoint-psoriasis-global-drug-forecast-and-market-analysis-to-2024#.Vw5P8_krK70
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics